Core Viewpoint - The development of traditional Chinese and Tibetan medicine in the province is being significantly advanced through top-level design, innovation, and reform, aiming for high-quality growth during the 14th Five-Year Plan period [1] Group 1: Infrastructure and Service Development - A national key hospital for traditional Chinese medicine has been established in Guoluo Prefecture, and a national regional medical center is expected to officially operate this year [1] - Hainan Prefecture has been selected as a national pilot area for the inheritance and innovation of traditional Chinese medicine [1] - The health management rates for traditional Chinese medicine among the elderly (over 65 years) and children (under 3 years) have reached 76.48% and 92.75%, respectively [1] Group 2: Integration and Research - The flagship hospital for integrated Chinese and Western medicine at Qinghai University has been completed, promoting deep integration of traditional medicine into public health systems [1] - The provincial hospitals and research institutes are actively participating in the construction of a high-altitude medical research center [1] - A national standard for Tibetan medicine disease classification and coding has been officially released, along with the establishment of 13 specialized databases and an information network platform for Tibetan medicine [1] Group 3: Cultural Promotion and Education - Seventeen provincial-level cultural education and publicity bases for traditional Chinese and Tibetan medicine have been established, along with activities to promote traditional medicine culture in schools [2] - A series of cultural events, including the "Twenty-Four Solar Terms Entering Qinghai Traditional Chinese and Tibetan Medicine," have been launched to engage the public [2] - The integration of traditional medicine culture with tourism and wellness is being actively promoted to expand external exchanges [2] Group 4: Healthcare Policy and Insurance - Sixty types of ethnic medicines have been added to the provincial medical insurance directory, enhancing the coverage of traditional medicine [2] - A total of 531 ethnic medicine formulations and 202 traditional Chinese medicine formulations have been included in the insurance payment system [2] - 564 out of 640 ethnic medicine service projects (88.13%) are now covered by medical insurance, significantly reducing the medical burden on rural communities [2]

Core Viewpoint - The Ministry of Industry and Information Technology and seven other departments have jointly issued the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to establish a collaborative development system for the entire traditional Chinese medicine industry chain by 2030 [1][2] Group 1: Goals and Objectives - By 2030, the plan aims to enhance the stable supply capacity of key traditional Chinese medicine raw materials and significantly improve the levels of digitalization and greening [1] - The plan includes cultivating a number of leading enterprises in the traditional Chinese medicine industry and establishing 60 high-standard raw material production bases [1] - It targets the approval and market launch of a batch of innovative traditional Chinese medicine products, including the cultivation of 10 major traditional Chinese medicine varieties [1][2] Group 2: Implementation Strategies - The plan outlines six key areas with 15 tasks, focusing on stabilizing supply, collaborative innovation, intelligent manufacturing, product promotion, and service system construction [1] - It emphasizes the need to revise production technology specifications and quality standards for key processing links in traditional Chinese medicine [2] - The use of artificial intelligence and big data to construct knowledge graphs for classic formulas and experiences from renowned traditional Chinese medicine practitioners is highlighted [1][2] Group 3: Quality Control and International Cooperation - The plan includes the establishment of a comprehensive quality control system and the development of new products from advantageous ethnic medicines [2] - It aims to enhance the clinical and market value of traditional Chinese medicine products and encourages international registration of advantageous traditional Chinese medicine products [2] - The plan calls for integrating related tasks into the high-quality development action system of key manufacturing industry chains [2]

Core Viewpoint - The article discusses the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" released by the Ministry of Industry and Information Technology and eight other departments, aiming to enhance the TCM industry through innovation, quality improvement, and sustainable development by 2030 [1][2]. Group 1: Policy Goals - By 2030, a collaborative development system for the entire TCM industry chain will be formed, with enhanced supply capabilities for key TCM raw materials and significant improvements in digitalization and greening levels [2][3]. - The plan aims to cultivate 60 high-standard TCM raw material production bases and support the approval of innovative TCM drugs, including the development of 10 new major TCM products [1][2]. Group 2: Key Tasks - Establish high-standard TCM raw material production bases, focusing on key raw material varieties and leveraging financial and technological advantages [3][4]. - Support the development of modern seed industries for TCM materials and enhance the supply monitoring and information service platform for TCM raw materials [3]. Group 3: Innovation and Technology - Strengthen the transformation and application of scientific achievements in the TCM field, fostering new productive forces in the industry [5][6]. - Utilize AI and big data to create knowledge graphs for classic formulas and enhance research capabilities in TCM pharmacology [6][7]. Group 4: Development of Ethnic Medicine - Promote the modernization of ethnic medicine, focusing on unique therapeutic effects and traditional practices, while establishing quality control systems for ethnic medicinal materials [7][8]. - Encourage the development of new products based on ethnic medicine and support collaboration among enterprises and research institutions [7]. Group 5: Market and Brand Development - Enhance the protection of intellectual property for traditional brands and improve production processes for existing TCM products to increase clinical and market value [8][9]. - Foster a unified and regulated market for TCM products, promoting high-quality and cost-effective offerings [8][9]. Group 6: Enterprise Development - Create a fair competitive environment to stimulate the potential and innovation of TCM enterprises, supporting the establishment of development funds and financial services for the industry [9][10]. - Encourage the cultivation of leading enterprises with ecological leadership and core competitiveness, promoting collaborative development across the industry chain [9][10].

Core Insights - The pharmaceutical safety situation in Yunnan Province is stable and improving, with zero major accidents over several years, and the biopharmaceutical industry revenue expected to exceed 320 billion yuan in 2024, reaching 323.17 billion yuan [1][2] Group 1: Pharmaceutical Safety - The drug inspection pass rate in Yunnan reached 99.53%, surpassing the national average of 99.4%, indicating a continuous improvement in drug safety [1] - The provincial drug regulatory authority has implemented a comprehensive regulatory mechanism, ensuring all drug operating and usage units are under supervision, with full coverage of high-risk drugs and vaccine production enterprises [1] - During the "14th Five-Year Plan" period, the number of administrative penalty cases related to "two products and one device" (drugs, cosmetics, and medical devices) increased more than twofold, with the value involved rising by 15.7 times, effectively purifying the market environment [1] Group 2: Industry Development - Yunnan's drug regulatory department has actively extended its role as a "service provider" to promote industry development, publishing 414 provincial standards for traditional Chinese medicine formula granules, with 48.6% of national reference medicinal materials coming from ethnic medicine [2] - The province has pioneered a "base evaluation + extended inspection" mechanism, extending quality management of traditional Chinese medicine from processing to the planting source, leading to the highest import volume and value of traditional Chinese medicine in the country in 2024 [2] - The digital transformation is key to enhancing regulatory efficiency, with the establishment of the "Drug Supervision Eye" platform utilizing big data and cloud computing for intelligent monitoring across the entire drug production, circulation, and usage chain [2] Group 3: Regulatory Achievements - Yunnan is the only province fully participating in the World Health Organization's vaccine national regulatory system assessment and international drug inspection cooperation program, providing significant support for the country's successful evaluation by the WHO [2] - The provincial drug regulatory authority has created a nationally recognized civilized unit and formed a large-scale, professional inspector team, ranking among the top in the southwest region [2] - Yunnan will continue to balance safety and development, promoting high-quality growth in the biopharmaceutical industry to ensure public medication safety and contribute to the health of the province [2]